At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.
St. Louis-based Cofactor will use the National Cancer Institute's clinical specimens in order to validate its Paragon assay platform.
Researchers who used the company's service presented data this week from analyses of sarcoma patients that they believe can help personalize care.
Validation results presented at the Association for Molecular Pathology meeting demonstrate that the test can be implemented clinically, replacing existing FISH and PCR assays.
In Cell this week: integrated genomic analysis of adult soft tissue sarcoma, positive selection has greater role in cancer than negative selection, and more.
Members of the ProfiLER trial identified actionable mutations in more than half of individuals with advanced cancers, though only a fraction received targeted therapy.
The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.
An epigenetic analysis showed that the tumors all shared a certain DNA methylation signature, but that methylation patterns varied between samples.
The partners aim to identify master regulators in the molecular networks of GIST patients that can serve as drug targets for existing treatments.
Rare germline mutations in cancer risk genes turned up in more than half of sarcoma patients tested by gene panel sequencing.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.